Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
Showing 761 - 780 results of 107,705 for search '(( e mean decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.54s Refine Results
  1. 761
    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease

    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease by Christine M. LaPash Daniels (796881)

    Published 2015
    “…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …”
    Save to List
    Saved in:
  2. 762
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 763
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 764
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 765
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 766
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 767
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 768
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 769
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 770
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 771
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 772
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 773
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 774
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 775
    Knockdown of factors in the 5′SS recognition complex U1 globally decreases intronic miRNA levels.

    Knockdown of factors in the 5′SS recognition complex U1 globally decreases intronic miRNA levels. by Maja M. Janas (200408)

    Published 2011
    Save to List
    Saved in:
  16. 776
    <i>Vps13</i> mutant flies show a decreased life span, age dependent impairment of locomotor function and neurodegeneration.

    <i>Vps13</i> mutant flies show a decreased life span, age dependent impairment of locomotor function and neurodegeneration. by Jan J. Vonk (3686662)

    Published 2017
    Save to List
    Saved in:
  17. 777
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 778
    The point mutants E559A, E563A and K567A display altered DNA-binding kinetics.

    The point mutants E559A, E563A and K567A display altered DNA-binding kinetics. by Bettina Hüntelmann (566945)

    Published 2014
    “…Whole cell extracts from STAT1-GFP-reconstituted U3A cells were incubated for 15 min with [<sup>33</sup>P]-labelled DNA containing a single STAT binding site (M67) and, subsequently, a 750-fold molar excess of unlabelled DNA was added for 0, 5 and 10 min, respectively, before the samples were loaded onto a native polyacrylamide gel. …”
    Save to List
    Saved in:
  19. 779
    <i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover.

    <i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover. by Melanie Norgate (234832)

    Published 2010
    Save to List
    Saved in:
  20. 780
    Decreasing RhoB expression by siRNA transfection does not change Ad5wt attachment or internalization.

    Decreasing RhoB expression by siRNA transfection does not change Ad5wt attachment or internalization. by Dragomira Majhen (462312)

    Published 2014
    Save to List
    Saved in:

Search Tools: